This year’s major cancer meetings, including the 2026 ASCO Annual Meeting and the 2026 SGO Annual Meeting on Women’s Cancer, highlighted important advances in ovarian cancer research. We sat down with Jennifer McClendon, Senior Manager of Mission Programming at the National Ovarian Cancer Coalition (NOCC), to discuss the most meaningful updates, where progress is being made, and what patients still need.
In this conversation, we talk about:
- Recent drug approvals in ovarian cancer
- How biomarker testing helps guide treatment options
- The importance of clinical trials at every stage
- Quality of life and accessibility of treatments
- And more
